{
    "news_source": "nasdaq",
    "news_id": "nasdaq_5b85b7c6ffca",
    "news_header": "AstraZeneca PLC (ADR) (AZN) has received an 87% rating using the P/E/Growth Investor model based on Peter Lynch&#x27;s strategy, indicating strong interest due to its solid fundamentals and valuation. This model evaluates stocks based on their price relative to earnings growth and balance sheet strength.",
    "news_original_title": "Peter Lynch Detailed Fundamental Analysis - AZN",
    "news_text": "Validea&#x27;s guru fundamental report shows that AstraZeneca PLC (ADR) (AZN) is a top-rated stock according to the P/E/Growth Investor model, achieving an 87% score which reflects its strong fundamentals and valuation. The report highlights the company&#x27;s performance in the Biotechnology &amp; Drugs industry and references Peter Lynch&#x27;s successful investment strategies.",
    "news_url": "https://www.nasdaq.com/articles/peter-lynch-detailed-fundamental-analysis-azn-18",
    "news_time": 1739192400.0,
    "news_categories": [
        "business",
        "markets"
    ],
    "news_source_lang": "en",
    "news_group": -1
}